Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)
NCT01268098
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
42
Enrollment
INDUSTRY
Sponsor class
Conditions
Hypoparathyroidism
Interventions
DRUG:
NPSP558
Sponsor
Shire